OakChart

Pyxis Oncology Inc

PYXSHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.64+0.01 (0.61%)
2026-11-12 05:14 CET
Market cap
196.16 USD m
Revenue, TTM
11.04 USD m
Net income, TTM
-86.71 USD m
Free cash flow, TTM
-70.93 USD m
EPS diluted, TTM
-1.29
P/E
-
Compare

Price

PYXS against its 20, 50 and 200-day averages
2050200beatmiss
2.003.004.006.1M12.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PYXSclose 1.6420-day 1.7350-day 2.41200-day 2.161.64

70.5% under the 52-week high of 5.55 on 26 Nov 2025. 52-week low 1.03 on 26 Dec 2025. Last 15 sessions, 32.8% high to low

Volume 0.56× normal · the line is the 50-bar volume average

Profile

PYXS
52-week range, 13% of the way up
1.035.55

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Employees56
IPOOct 08, 2021
Beta1.42
ATR, 14d0.15
Rel volume0.56
Short float4.40%
Insider own13.92%
Inst own33.14%

Snapshot

6 groups

Valuation

Index-
Market Cap196.16M
Enterprise Value156.52M
Income-86.71M
Sales11.04M
Book/sh0.49
Cash/sh0.48
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees56
IPOOct 08, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S17.77
P/B3.31
P/C3.44
P/FCF-
EV/EBITDA-
EV/Sales14.18
Quick Ratio2.96
Current Ratio2.96
Debt/Eq0.42
LT Debt/Eq0.38
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.29
EPS next Y-0.83
EPS next Q-0.22
EPS this Y13.54%
EPS next Y25.40%
EPS next 5Y13.10%
EPS past 3/5Y29.49% -27.93%
Sales past 3/5Y- -
EPS Y/Y TTM18.90%
Sales Y/Y TTM291.42%
EPS Q/Q31.96%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.13.73% -

Ownership

Insider Own13.92%
Insider Trans0.00%
Inst Own33.14%
Inst Trans-0.14%
ROA-95.09%
ROE-157.51%
ROIC-152.58%
Gross Margin42.53%
Oper. Margin-807.83%
Profit Margin-785.54%
SMA20-5.39%
SMA50-31.90%
SMA200-23.96%
Trades-

Technical

Shs Outstand119.61M
Shs Float102.96M
Short Float4.40%
Short Ratio3.80
Short Interest4.53M
52W High5.55 -70.45%
52W Low1.03 59.22%
Volatility8.27% 7.95%
ATR (14)0.15
RSI (14)36.66
Beta1.42
Rel Volume0.56
Avg Volume1.19M
Volume665,413

Performance

Perf Week-1.20%
Perf Month-11.35%
Perf Quarter-45.51%
Perf Half Y-37.40%
Perf YTD42.61%
Perf Year-64.11%
Perf 3Y7.19%
Perf 5Y-86.72%
Perf 10Y-
Recom1.20
Target Price8.22
Prev Close1.63
Price1.64
Change %0.61%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Aug 03, 2026InitiatedWWells FargoOverweight$12+631.7%
May 05, 2026InitiatedWWedbushOutperform$6+265.9%
Nov 03, 2025ResumedSStifelBuy$9+448.8%
Sep 04, 2025InitiatedGGuggenheimBuy$5+204.9%
Nov 21, 2024DowngradeWWilliam BlairOutperform → Mkt Perform
Nov 08, 2024InitiatedSStephensOverweight$13+692.7%
Aug 08, 2024InitiatedSStifelBuy$10+509.8%
May 07, 2024ResumedJJefferiesBuy$10+509.8%
Feb 09, 2024InitiatedBBTIG ResearchBuy$8+387.8%
Jan 23, 2024InitiatedLLeerink PartnersOutperform$12+631.7%

Peers

Mkt cap
TickerCompanyMkt cap
STROSutro Biopharma Inc170.12M
BCYCBicycle Therapeutics Plc ADR186.57M
BCAXBicara Therapeutics Inc699.06M
ZYMEZymeworks BC Inc2.02B
ADCTAdc Therapeutics SA204.27M
PDSBPDS Biotechnology Corp107.11M
IPHAInnate Pharma ADR177.60M
ALXOAlx Oncology Holdings Inc154.87M
CHRSCoherus Oncology Inc90.02M
CUECue Biopharma Inc135.55M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Dupont JakobDirectorJun 30 '26Proposed Sale3.0635,000107,034Jun 30 04:13 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 200
  • Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO) (GlobeNewswire)
  • Pyxis Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.61%
  • Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +8.88%
  • Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering (GlobeNewswire)
  • Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering (GlobeNewswire) -19.66%
  • Pyxis Oncology stock falls on public offering announcement (Investing.com)
  • Pyxis Oncology Announces Proposed Public Offering (GlobeNewswire)
  • Pyxis Oncology shares fall 7% despite updated MICVO trial results (InvestorsHub) -13.11%
  • Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) (GlobeNewswire)
  • Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) (GlobeNewswire)
  • Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board (GlobeNewswire)
  • Pyxis Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.17%
  • Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones (GlobeNewswire) -5.35%
  • Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones (GlobeNewswire) +5.24%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.240-0.278-0.2400.000.009
2026Q22026-08-13-0.400-0.350-0.3960.000.039
2026Q12026-05-14-0.370-0.364-0.3670.000.009
2025Q42026-03-23-0.280-0.344-0.28911.030.009
2025Q32025-11-03-0.350-0.334-0.3520.000.008
2025Q22025-08-14-0.300-0.352-0.2962.820.006
2025Q12025-05-15-0.350-0.294-0.3470.000.005
2024Q42025-03-18-0.620-0.320-0.5970.000.007
2024Q32024-11-12-0.350-0.318-0.3490.000.008
2024Q22024-08-14-0.290-0.338-0.2860.000.006
2024Q12024-05-14-0.060-0.239-0.06416.154.135
2023Q42024-03-21-0.340-0.475-0.3490.000.206
2023Q32023-11-07-0.560-0.507-0.5580.000.003
2023Q22023-08-11-0.410-0.647-0.4140.000.634
2023Q12023-05-11-0.540-0.899-0.5440.000.004
2022Q42023-03-22-1.040-0.930-1.0330.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-8.950-4.400-2.3580.000.00
2022FY-3.650-3.664-3.6540.000.00
2023FY-1.850-1.958-1.8490.000.17
2024FY-1.320-1.092-1.32316.1516.11
2025FY-1.280-1.334-1.28313.862.84
2026FY--1.107--0.02
2027FY--0.826--3.13
2028FY--0.840--15.79
2029FY--0.745--42.75
2030FY--0.410--122.37

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-057000.030.000.18
2026Q4S2026-10-277000.030.000.18
2026Q4S2026-08-137010.030.000.18
2026Q4S2026-07-066100.030.000.20
2026Q4S2026-07-016000.030.000.18
2026Q4S2026-06-097000.030.000.18
2026Q4S2026-05-148000.020.000.18
2026Q4S2026-05-048000.020.000.18
2026Q4S2026-03-247000.030.000.18
2026Q4S2026-03-236000.030.000.18
2026Q4S2026-01-266000.000.000.00
2026Q4S2025-11-245000.000.000.00
2026Q4S2025-11-234000.000.000.00
2026Q4S2025-11-115000.000.000.00

Estimate history

EPS, annual-0.081-0.374-2.358-3.654-1.849-1.323-1.281-1.2909
Period2019202020212022202320242025TTM
EPS, quarterly-0.349-0.597-0.347-0.296-0.352-0.289-0.367-0.396-0.239
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000016.14613.85811.04
Period2019202020212022202320242025TTM
Sales, quarterly0002.82011.038000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual34.30934.30932.22334.95944.75559.96862.6983.512
Period2019202020212022202320242025MRQ
Shares, quarterly59.4559.96861.63162.01862.1562.6962.83163.43583.512
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue11.0413.8616.150.000.000.000.000.00
Cost of Goods Sold Incl. D&A6.346.903.462.001.841.250.410.00
Gross Profit4.696.9612.69-2.00-1.84-1.25-0.410.00
Selling, General and Administrative Excl. Other93.8691.3881.1980.20121.6468.4712.482.88
Research and Development73.2272.1057.3547.8984.2949.808.631.22
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-89.17-84.42-68.50-82.20-123.48-69.72-12.89-2.88
Interest Expense---0.000.000.000.000.00
Unusual Expense0.000.0020.960.000.006.230.000.00
Net Income Before Taxes-85.61-78.23-79.50-73.79-120.72-75.97-12.83-2.77
Income Taxes1.101.39-2.160.000.000.000.000.00
Consolidated Net Income-86.71-79.62-77.33-73.79-120.72-75.97-12.83-2.77
Net Income From Continuing Operations-86.71-79.62-77.33-73.79-120.72-75.97-12.83-2.77
Net Income-86.71-79.62-77.33-73.79-120.72-75.97-12.83-2.77
EPS (Recurring)-1.04-1.28-1.07-1.85-3.65-2.22-0.37-0.08
EPS (Basic, Before Extraordinaries)-1.29-1.28-1.32-1.85-3.65-2.36-0.37-0.08
EPS (Diluted)-1.29-1.28-1.32-1.85-3.65-2.36-0.37-0.08
EBITDA-85.21-79.91-65.51-80.20-121.64-68.47-12.48-2.88
Non-Operating Income (Expense)3.566.189.968.412.76-0.030.070.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.719.3210.2316.9511.956.370.020.00
Price To Sales Ratio17.635.165.65-----
Gross Margin42.5350.2278.59-----
Operating Margin-807.83-609.18-424.23-----
Net Margin-785.54-574.55-478.95-----
Shares Outstanding83.5162.6959.9744.7534.9632.2234.3134.31
Market Capitalization196.16196.1692.7779.7343.67376.37373.63-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.0011.040.002.820.000.00
Cost of Goods Sold Incl. D&A0.300.300.465.290.530.540.550.55
Gross Profit-0.30-0.30-0.465.75-0.532.29-0.55-0.55
Selling, General and Administrative Excl. Other20.2225.6923.9024.0522.9322.0422.3618.55
Research and Development16.3215.8119.5921.5017.3516.6817.0413.47
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-20.52-25.99-24.36-18.30-23.46-19.75-22.91-19.11
Interest Expense0.00-------
Unusual Expense0.000.000.000.000.000.000.0020.96
Net Income Before Taxes-19.98-25.35-23.27-17.00-22.00-18.07-21.16-37.73
Income Taxes0.000.000.001.100.000.280.00-2.16
Consolidated Net Income-19.98-25.35-23.27-18.11-22.00-18.35-21.16-35.57
Net Income From Continuing Operations-19.98-25.35-23.27-18.11-22.00-18.35-21.16-35.57
Net Income-19.98-25.35-23.27-18.11-22.00-18.35-21.16-35.57
EPS (Recurring)-0.24-0.40-0.37-0.29-0.35-0.30-0.35-0.35
EPS (Basic, Before Extraordinaries)-0.24-0.40-0.37-0.29-0.35-0.30-0.35-0.60
EPS (Diluted)-0.24-0.40-0.37-0.29-0.35-0.30-0.35-0.60
EBITDA-20.22-25.69-23.90-15.40-22.93-19.21-22.36-18.55
Non-Operating Income (Expense)0.540.641.091.291.461.681.762.33
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.335.531.211.642.432.380.030.05
Price To Sales Ratio17.6317.456.695.2049.2524.15-5.76
Gross Margin---52.12-81.03--
Operating Margin----165.75--700.35--
Net Margin----164.03--650.85--
Shares Outstanding83.5163.4362.8362.6962.1562.0261.6359.97
Market Capitalization196.16190.7091.7371.60137.6868.1460.3592.77

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments68.33128.40120.77180.76276.218.0819.69
Short Term Receivables0.700.000.020.600.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets3.084.043.815.252.470.020.01
Total Current Assets72.11132.44124.60186.61278.678.1019.70
Net Property, Plant & Equipment19.4122.1424.8124.771.241.940.08
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets0.002.6024.310.00---
Deferred Tax Assets3.00------
Other Assets0.000.000.000.000.110.110.03
Total Assets94.52157.18173.73211.38280.0210.1519.81
Short Term Debt Incl. Current Port. of LT Debt1.691.451.230.000.170.610.01
Accounts Payable10.884.863.907.1011.951.080.49
Income Tax Payable-----0.060.11
Other Current Liabilities8.5511.3720.6324.546.591.930.12
Total Current Liabilities21.1317.6825.7631.6318.713.690.73
Long Term Debt16.9818.7520.1018.920.000.170.01
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities3.00-2.16----
Other Liabilities0.000.000.000.000.000.000.00
Total Liabilities41.1136.4348.0250.5518.713.850.74
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0021.9421.94
Common Equity53.41120.75125.70160.82261.31-15.64-2.87
Total Shareholders Equity53.41120.75125.70160.82261.316.3019.07
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity53.41120.75125.70160.82261.316.3019.07
Total Liabilities & Stockholders Equity94.52157.18173.73211.38280.0210.1519.81
Book Value Per Share0.852.012.814.608.11-0.46-0.08
Tangible Book Value Per Share0.851.972.274.608.11-0.46-0.08
Full-Time Employees5644507556--
Price to Book Ratio3.310.600.580.231.35-5.23-
Return on Assets-63.27-46.74-38.32-49.13-52.37-85.64-
Return on Equity-91.43-62.75-51.51-57.19-56.78-101.15-
Return on Invested Capital-113.12-55.43-50.61-67.16-29.07-198.51-14.53
Quick Ratio3.417.494.845.9014.902.2026.88
Current Ratio3.417.494.845.9014.902.2026.88

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-86.71-79.62-77.33-73.79-120.72-75.97-12.83-2.77
Depreciation3.964.512.981.931.841.250.410.00
Other Funds (Non Cash)9.949.6628.5012.8225.0532.720.040.03
Funds from Operations-72.81-65.44-45.85-59.05-93.84-42.00-12.37-2.74
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital1.891.94-11.82-11.664.506.682.290.51
Cash from Operating Activities-70.93-63.50-57.67-70.71-89.33-35.33-10.08-2.24
Capital Expenditures0.00-0.01-0.24-6.73-6.40-0.54-1.480.00
Net Assets From Acquisitions0.000.000.006.660.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments16.6458.878.39-104.780.00-0.050.000.00
Purchase of Investments-63.36-107.00-160.12-196.830.00-0.050.000.00
Sale Or Maturity of Investments80.00165.87168.5192.050.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities16.6458.868.15-104.85-6.40-0.59-1.480.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock49.410.7459.576.370.18304.040.0421.95
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock49.410.7459.576.370.18304.040.0421.95
Proceedsfrom Stock Options48.450.1159.276.250.00303.880.0421.95
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.18-0.15-0.24-0.450.000.000.000.00
Other Financing Activities Uses-0.18-0.15-0.24-0.450.000.000.000.00
Cash from Financing Activities49.220.5959.335.930.18304.040.0421.95
Net Change in Cash-5.06-4.059.81-169.63-95.55268.13-11.5319.72
Free Cash Flow-70.93-63.51-57.91-77.44-95.73-35.87-11.57-2.24
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments57.0434.4742.4968.3377.7390.42
Short Term Receivables0.000.000.000.700.003.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.082.273.083.085.346.54
Total Current Assets59.1336.7345.5772.1183.0799.96
Net Property, Plant & Equipment17.6418.1918.7319.4120.1020.77
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.002.432.49
Deferred Tax Assets---3.00--
Other Assets0.000.000.000.000.000.00
Total Assets76.7754.9264.3094.52105.60123.22
Short Term Debt Incl. Current Port. of LT Debt1.891.821.761.691.631.57
Accounts Payable8.123.274.9910.889.769.41
Other Current Liabilities9.9322.389.798.558.006.70
Total Current Liabilities19.9427.4716.5321.1319.3817.68
Long Term Debt15.5116.0116.5016.9817.4417.89
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---3.00--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities35.4543.4833.0341.1136.8335.57
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity41.3211.4431.2753.4168.7887.64
Total Shareholders Equity41.3211.4431.2753.4168.7887.64
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity41.3211.4431.2753.4168.7887.64
Total Liabilities & Stockholders Equity76.7754.9264.3094.52105.60123.22
Book Value Per Share0.490.180.500.851.111.41
Tangible Book Value Per Share0.490.180.500.851.071.37
Full-Time Employees---56--
Price to Book Ratio3.316.051.711.041.570.66
Return on Assets-95.09-99.62-81.67-63.27-64.53-58.07
Return on Equity-157.51-179.10-121.66-91.43-87.28-74.80
Return on Invested Capital-35.17-92.34-48.72-25.72-25.52-17.39
Quick Ratio2.961.342.763.414.295.65
Current Ratio2.961.342.763.414.295.65

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-19.98-25.35-23.27-18.11-22.00-18.35
Depreciation0.300.300.462.900.530.54
Other Funds (Non Cash)1.245.571.201.932.752.32
Funds from Operations-18.45-19.47-21.61-13.28-18.73-15.50
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.151.27-4.392.865.45-1.76
Cash from Operating Activities-16.29-18.21-26.00-10.43-13.28-17.26
Capital Expenditures0.000.000.000.00-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-37.2921.3016.3716.2611.4815.30
Purchase of Investments-49.37-3.00-10.990.00-14.56-41.10
Sale Or Maturity of Investments12.0824.3027.3616.2626.0456.40
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-37.2921.3016.3716.2611.4715.30
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock38.6210.050.000.740.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock38.6210.050.000.740.000.00
Proceedsfrom Stock Options38.3410.000.000.110.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.04-0.05-0.03-0.07-0.01-0.07
Other Financing Activities Uses-0.04-0.05-0.03-0.07-0.01-0.07
Cash from Financing Activities38.599.99-0.030.67-0.01-0.07
Net Change in Cash-15.0013.09-9.666.50-1.81-2.03
Free Cash Flow-16.29-18.21-26.00-10.43-13.29-17.26

Revenue breakdown

Milestone2025: 2.82M
Royalty2024: 8.15M
Sale of Royalty Rights2024: 8.00M 2025: 11.04M
United States2024: 16.15M 2025: 13.86M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.40%4.5M103.0M1.21M
2026-10-154.22%4.3M102.9M1.25M
2026-09-304.75%4.9M102.8M1.22M
2026-09-156.52%4.7M71.8M1.32M
2026-08-315.82%4.0M68.1M1.17M
2026-08-146.50%4.4M68.1M1.19M
2026-07-318.06%4.2M51.8M972.16K
2026-07-156.29%3.3M51.8M857.96K
2026-06-304.42%2.3M51.8M746.00K
2026-06-153.90%2.0M51.8M500.97K
2026-05-293.37%1.7M51.7M487.21K
2026-05-153.50%1.8M51.7M440.48K
2026-04-303.88%2.0M51.2M399.83K
2026-04-154.67%2.3M48.6M441.26K
2026-03-315.48%2.7M48.5M693.06K
2026-03-135.18%2.5M48.1M1.15M
2026-02-275.25%2.5M48.1M1.20M
2026-02-135.08%2.4M48.1M1.25M
2026-01-304.96%2.4M48.1M1.30M
2026-01-154.80%2.3M48.1M1.28M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.851.401.3025.6871.000.000.989-0.0110.000
call1.000.351.100.0010.1130.000.000.883-0.0340.001
call1.500.050.400.403.37151.001.000.722-0.0310.001
call2.000.000.350.214.6223380.000.534-0.0270.001
call2.500.000.350.403.08479.000.000.262-0.0150.001
call5.000.000.200.205.4381.000.000.186-0.0210.001
call7.500.000.750.006.5920.000.000.166-0.0240.001
put0.500.000.750.000.0000.000.00-0.052-0.0210.000
put1.000.000.750.0011.8370.000.00-0.117-0.0340.001
put1.500.000.750.156.63418.000.00-0.278-0.0310.001
put2.000.100.550.503.06417.000.00-0.466-0.0260.001
put2.500.651.350.957.0882220.00-0.738-0.0140.001
put5.002.903.903.0010.2150.000.00-0.814-0.0200.001
put7.505.406.400.0011.5150.000.00-0.834-0.0230.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-064Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-03SCHEDULE 13G/ASEC
2026-10-21DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-21SEC
2026-10-09PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-09SEC
2026-10-09SCHEDULE 13G/ASEC
2026-10-094/A2026-10-01SEC
2026-10-05SCHEDULE 13GSEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-02SCHEDULE 13G/ASEC
2026-10-018-KCurrent report2026-09-29SEC
2026-10-01424B5SEC
2026-09-29424B5SEC
2026-09-29424B5SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-088-KCurrent report2026-09-03SEC
2026-08-28424B2SEC
2026-08-27EFFECTEffectiveness filing by commission orderSEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-20S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-10SCHEDULE 13GSEC
2026-07-103Initial statement of beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-028-KCurrent report2026-06-30SEC
2026-07-02SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GordonMD Global Investments LP15.82%
PFIZER INC11.10%
Laurion Capital Management LP5.98%
VANGUARD CAPITAL MANAGEMENT LLC3.28%
Atle Fund Management AB1.53%
BlackRock, Inc.1.37%
Palo Alto Investors LP1.36%
MARSHALL WACE, LLP1.31%
RENAISSANCE TECHNOLOGIES LLC1.22%
GEODE CAPITAL MANAGEMENT, LLC0.85%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.24%
VANGUARD EXTENDED MARKET INDEX FUND0.88%
iShares Biotechnology ETF0.59%
Fidelity Extended Market Index Fund0.31%
iShares Micro-Cap ETF0.26%
Fidelity Nasdaq Composite Index Fund0.15%
Fidelity Total Market Index Fund0.12%
Ultra-Small Company Market Fund0.11%
Fidelity Series Total Market Index Fund0.10%
VANGUARD BALANCED INDEX FUND0.04%

OakChart. PYXS. Cached 15 minutes.